Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Introducing a Special Issue of Biofeedback Magazine

Introducing a Special Issue of Biofeedback Magazine Biofeedback | Spring 2022 Biofeedback Association for Applied Psychophysiology & Biofeedback Volume 50, Issue 1, pp. 1–2 www.aapb.org DOI: 10.5298/1081-5937-50.1.01 Fro From m the the Guest Guest Editors Editors 1 2 Inna Khazan, PhD, BCB, BCB-HRV, and Donald Moss, PhD, BCB, BCB-HRV 1 2 Harvard Medical School, Boston, MA; College of Integrative Medicine and Health Sciences, Saybrook University, Oakland, CA In 2001, AAPB and ISNR joined hands to establish a Task supported by a growing number of randomized controlled Force to develop guidelines for the evaluation of clinical trials on both biofeedback and neurofeedback, the chapter efficacy in biofeedback and neurofeedback. Theodore rates biofeedback and neurofeedback as Level Four – LaVaque et al. (2002) published the Task Force report, Efficacious for PTSD. creating an efficacy rating scale for biofeedback and Next, this special issue includes a chapter by Sarah neurofeedback interventions. The efficacy rating runs as Prinsloo on the newer and still emerging research on follows, based on the credibility of current published neurofeedback for chemotherapy-induced peripheral neu- research on specific disorders: ropathy (CIPN). Prinsloo reviews two randomized con- trolled trials and one case study on neurofeedback for Efficacious and specific (Level 5) CIPN and rates this application area http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biofeedback Allen Press

Introducing a Special Issue of Biofeedback Magazine

,; ,
Biofeedback , Volume 50 (1): 2 – May 31, 2022

Loading next page...
 
/lp/allen-press/introducing-a-special-issue-of-biofeedback-magazine-0UsYUerlUD
Publisher
Allen Press
Copyright
© Association for Applied Psychophysiology & Biofeedback
ISSN
1081-5937
eISSN
2158-348X
DOI
10.5298/1081-5937-50.1.01
Publisher site
See Article on Publisher Site

Abstract

Biofeedback | Spring 2022 Biofeedback Association for Applied Psychophysiology & Biofeedback Volume 50, Issue 1, pp. 1–2 www.aapb.org DOI: 10.5298/1081-5937-50.1.01 Fro From m the the Guest Guest Editors Editors 1 2 Inna Khazan, PhD, BCB, BCB-HRV, and Donald Moss, PhD, BCB, BCB-HRV 1 2 Harvard Medical School, Boston, MA; College of Integrative Medicine and Health Sciences, Saybrook University, Oakland, CA In 2001, AAPB and ISNR joined hands to establish a Task supported by a growing number of randomized controlled Force to develop guidelines for the evaluation of clinical trials on both biofeedback and neurofeedback, the chapter efficacy in biofeedback and neurofeedback. Theodore rates biofeedback and neurofeedback as Level Four – LaVaque et al. (2002) published the Task Force report, Efficacious for PTSD. creating an efficacy rating scale for biofeedback and Next, this special issue includes a chapter by Sarah neurofeedback interventions. The efficacy rating runs as Prinsloo on the newer and still emerging research on follows, based on the credibility of current published neurofeedback for chemotherapy-induced peripheral neu- research on specific disorders: ropathy (CIPN). Prinsloo reviews two randomized con- trolled trials and one case study on neurofeedback for Efficacious and specific (Level 5) CIPN and rates this application area

Journal

BiofeedbackAllen Press

Published: May 31, 2022

There are no references for this article.